ライフサイエンスコーパス: excipient

1 drug that contains polyethylene glycol as an excipient.

2 drying, with cyclodextrin used as stabiliser excipient.

3 and by the addition of a branched polymeric excipient.

4 ini-B, or B-YL), and Lactose or Trehalose as excipient.

5 blended granules using Neusilin(R) US2 as an excipient.

6 ntrol, sham mice received patches containing excipient.

7 tein stability and activity as a formulation excipient.

8 rug micelles containing minimal solubilizing excipient.

9 of trehalose (i.e., as low as 2% w/v) as an excipient.

10 n terms of pH, salt concentration, and added excipients.

11 h a focus on the role of coating formulation excipients.

12 d dosage form, embedded within commonly used excipients.

13 Canada since 1995 that include phthalates as excipients.

14 than those produced by common pharmaceutical excipients.

15 on of APIs relative to common pharmaceutical excipients.

16 induced by protein cofactors and formulation excipients.

17 the sodium salt of the drug and formulation excipients.

18 t significant interferences from formulation excipients.

19 eters and are a complex mixture of drugs and excipients.

20 nsfer reactions and high viscosity of dosing excipients.

21 ble aqueous dispersions without the need for excipients.

22 ve pharmaceutical ingredient and a number of excipients.

23 biotherapeutic solubility and the effects of excipients.

24 optimize its formulation with water-soluble excipients.

25 a framework for the data-driven selection of excipients.

26 ure containing representative pharmaceutical excipients.

27 ycol (PEG), polysorbate and tromethamine are excipients.

28 bilizing mutations and the role of potential excipients.

29 anti-inflammatory drugs, COVID vaccine, and excipients.

30 olloidal stability in the presence of common excipients.

31 t that affords key benefits over traditional excipients.

32 tion methods, without the use of polymers or excipients.

33 ablets that include bulking agents and other excipients.

34 ed tests that use medications containing PEG excipients.

35 88 candidate drugs and one of 2,686 approved excipients.

36 a whole, i.e., the active ingredient(s) and excipients.

37 in the presence of degradation products and excipients.

38 resence of each other and in the presence of excipients.

39 Testing in vitro revealed 25 excipient activities, ranging from low-nanomolar to high

40 substances as well as the most commonly used excipients/adulterants found in seized illicit material.

41 ml excipient twice a day (n = 43) or 2.5 ml excipient alone twice daily (n = 37) along with conventi

42 s containing divalent cations and/or CMCS as excipients, although specific effects were dependent on

43 pray dried together with a selected group of excipients, among which glucose was evidenced as the bes

44 40, a common azo dye excipient and a potent inhibitor of OATP2B1, decreased t

45 ion of allergic milk proteins in the lactose excipient and found the smear band by silver staining, w

46 Atf4 (-/-) mice treated with asparaginase or excipient and further explored selected responses in liv

47 d efficiently deliver chemical drugs without excipients and biologics drugs in the presence of sugar

48 fect of pH on resolution, (ii) the effect of excipients and buffering agents, (iii) the performance o

49 echniques cannot resolve the distribution of excipients and drugs at the submicrometer scale.

50 d in solution in the presence of stabilizing excipients and frozen after gradual supercooling prior t

51 ers are mainly focused on their functions as excipients and inert carriers of other pharmacologically

52 should use materials safe as pharmaceutical excipients and its formulation (nanomedicine) should hav

53 All high molecular weight auxiliary excipients and mannitol containing formulations were uns

54 w members to the library of functional lipid excipients and open a novel and effective synthetic path

55 r dosage forms in a single-step with minimal excipients and operations.

56 ten incorporate non-validated pharmaceutical excipients and other features that limit their clinical

57 ted with common and validated pharmaceutical excipients and production processes provide a versatile

58 efore, understanding the interaction between excipients and protein therapeutics in the solid state i

59 t can encapsulate IPV along with stabilizing excipients and release immunogenic IPV over the course o

60 tides (covalently fused to the protein or as excipients) and that lipid nanoparticles (LNPs) encapsul

61 ation, 6 RX drug products included DBP as an excipient, and 45 specified the use of diethyl phthalate

62 maging of specific ion species for the drug, excipient, and coating materials.

63 mixtures with heroin and other adulterants, excipients, and bulking agents has placed an emphasis on

64 ed heparin; compounds tested included drugs, excipients, and larger glycosaminoglycans and their semi

65 g certain active pharmaceutical ingredients, excipients, and nutraceuticals, impart their bitter tast

66 addressed as raw materials, drug substance, excipients, and the fully formed and stored product.

67 el catalyst, an inorganic base, and an inert excipient are employed as a fast, safe, and user-friendl

68 Some excipients are foods or substances derived from foods, r

69 Bespoke formulations and excipients are now required, with trehalose(2), sucrose

70 Excipients are substances in pharmaceuticals other than

71 Drugs are coated onto balloons using excipients as drug carriers to facilitate adherence and

72 e of signal interference from pharmaceutical excipients, as well as for characterizing structural pro

73 per lipid ratio, acidic dialysis buffer, and excipient-assisted nebulization buffer, demonstrates exc

74 with heroin and other common adulterants and excipients at 30:1 (compound/fentanyl) concentration rat

75 cal companies face in the use of novel lipid excipients at each stage of development, and propose con

76 in the number of components assigned in the excipients batch using FTICR-MS, compared to the numbers

77 rm guest/host complexes with the widely used excipient, beta-cyclodextrin (betaCD).

78 ition to being a food dye and pharmaceutical excipient, Brilliant Black BN is commonly used within ca

79 Inavir inhaler powder and lactose used as an excipient but negative for Laninamivir.

80 iagnostic tool for confirming allergy to PEG excipient but not to the vaccine as a positive result in

81 ad no covalent chemical interaction with the excipients, but the crystallinity of AmB was reduced in

82 a viscosity enhancer are beneficial coating excipients, but the inclusion of surfactant is detriment

83 A peptide sample and the TFA excipient can be studied simultaneously by FT-IR and 2D

84 nd show that agents used as commercial lipid excipients can activate nutrient-sensitive receptors on

85 maceutical formulations, the interference of excipients can be avoided, a feature cannot achieved by

86 These well-known excipients can be used as admixtures to treat NPC1 disor

87 , or a mixture of sugars and amino acids, as excipients can convert vaccines containing aluminum salt

88 The activation effects of such excipients can reach into the tens and hundreds of fold.

89 viously shown that polyethylene glycol (PEG) excipients can selectively enhance the oral bioavailabil

90 -water mutual diffusivity in the presence of excipient cannot generally be taken as a constant.

91 rmaceutical ingredients, targeting moieties, excipients, carriers, or structural components in drug d

92 pediatric medicine that contains Ace-K as an excipient (Children's Motrin(TM)).

93 rial vessel using a variety of biocompatible excipients coated on the balloons.

94 s were dependent on the specific peptide and excipient combinations.

95 nufactured lots of Vimkunya or placebo (same excipient composition without chikungunya virus virus-li

96 d under added salt (0-140 mM NaCl) and added excipients concentrations, as typically found in biother

97 conditions (sequences, interaction partners, excipients, conformational states, etc.) to determine st

98 Excipients, considered "inactive ingredients," are a maj

99 The first group of excipients consists of phenolic and aniline substrates a

100 We examine three excipient/contaminant systems, glycerin/diethylene glyco

101 Although most excipients deserve their status as inert, many approved

102 te, but the new formulation also contains an excipient designed to enhance absorption.

103 Further investigations into buffer excipients doubled the presence of monomeric monobody in

104 the future clinical translation of sex- and excipient-driven therapeutic approaches.

105 nocarriers could be modulated by varying the excipients (e.g., nature and quantities), the formulatio

106 ty are examined as ways to minimize or avoid excipient effects, particularly for very polar compounds

107 to systematically characterize structure and excipient effects.

108 Mannitol is an essential excipient employed in orally disintegrating tablets due

109 y was relatively low (<8%) in the absence of excipient emulsions due to the crystalline nature of the

110 Overall, this study shows that excipient emulsions may increase the bioaccessibility of

111 The effects of adding these excipient emulsions on the concentration, bioaccessibili

112 The use of excipient emulsions to increase the bioaccessibility of

113 and TAC values of the tomato sauces with the excipient emulsions were significantly higher than those

114 considerably lower for tomato sauces without excipient emulsions, being around 24-31%, 69-71%, and 45

115 , 73-112%, and 67-94% for tomato sauces with excipient emulsions, respectively.

116 d in the tomato sauce samples containing the excipient emulsions.

117 and mature adult (16-week) mice with drug or excipient for 1 week and conducted RNA-Seq and functiona

118 systems usually substitute one solubilizing excipient for another, bringing new issues to consider.

119 Hypromellose is an excellent excipient for formulation of classical dosage forms and

120 of reducing sugars in the formulation of an excipient for the stabilization of dried protein is not

121 Recent developments in cyclodextrins as excipients for anesthetics may soon culminate in their i

122 principles that should help develop targeted excipients for bioavailability and taste modification in

123 o the arterial wall include finding suitable excipients for drug formulation to enable drug release t

124 o design improved low-calorie sweeteners and excipients for food and pharmaceutical preparations.

125 se degradable polymers were then employed as excipients for the stabilization of the therapeutic prot

126 NMR has the potential to be applied to other excipient formulation components in the presence of vari

127 Polyethylene glycol (PEG) is the excipient found in the mRNA COVID-19 vaccines.

128 Alternatives like 'top-down' fine milling of excipient-free injectable drug suspensions are not yet c

129 , unlike present technologies, deliver pure, excipient-free protein by mechanically releasing it from

130 This unique stabilization and excipient-free release synergy offers a practical, scala

131 0 succinate (TPGS) is an important polymeric excipient frequently used in drug formulation.

132 possible to differentiate between batches of excipients from differences in the identified components

133 Therefore, a comparison between excipients from different suppliers and batches to batch

134 is study demonstrates for the first time how excipient functionality can be harnessed to develop sex-

135 oreover, the activations afforded by the two excipient groups are additive, resulting in up to a comp

136 In cellular models, five excipients had fingerprints predictive of system-level t

137 The nature of the PLGA polymer excipient has a dominant influence on the performance of

138 embly of EB-CPT and PTX without adding other excipients has nearly 100 % drug loading efficiency (DLE

139 HPMC, being a traditional pharmaceutical excipient, has an irreplaceable role in the development

140 of the active pharmaceutical ingredients and excipients held in the product.

141 Excipients, historically regarded as inert, are now bein

142 complex structures and compositions of drug excipients impact performance of the formulation in vivo

143 First, the excipient improved stabilization of biopharmaceuticals t

144 ved as a generally recognized as safe (GRAS) excipient in 1985 by the United States Food and Drug Adm

145 s present in its native (unbound) form as an excipient in a range of products.

146 Polysorbate (PS) is a widely used polymeric excipient in biotherapeutic formulations to stabilize an

147 r results underscore the significance of the excipient in DCB design and suggest that coating microst

148 cid residues, and they are widely used as an excipient in food and pharmaceutical industries.

149 The lactose excipient in Inavir inhaler powder was supposed to conta

150 nent of human lung surfactant and is used as excipient in medical aerosol therapy.

151 om milk, lactose is a food ingredient and an excipient in medicines.

152 an ingredient in foods and beverages and an excipient in pediatric medicines.

153 an be used to ascertain the presence of this excipient in peptide samples for quality assessment.

154 ECH-CL-CMRSs could potentially be used as an excipient in pharmaceutical and food/food supplement pro

155 pound, the concentration-time profile of the excipient in plasma from rats dosed both orally and intr

156 e and the interference from proteins and the excipient in the formulation matrix make it a challenge

157 arameters for coated MNs include the role of excipients in assisting dissolution from the MNs, the in

158 mAb but not associated with the formulation excipients in both light-irradiated and heat-stressed mA

159 varying molecular weight (MW) used widely as excipients in drugs and other products, including the mR

160 use of Gelucire 44/14 and polysorbate 80 as excipients in drugs, they are also widely used as cosmet

161 ique structural and functional role of lipid excipients in LNPs, there is limited specific global reg

162 therapeutic categories may use DBP or DEP as excipients in oral dosage forms.

163 e study focused on investigating the role of excipients in protein aggregation during the production

164 ture of two clopidogrel polymorphs and three excipients in solid tablets with a pixel dwell time of 2

165 oduct concentration and bioactivity avoiding excipients in spray-drying phase.

166 Cyclodextrins are well-known excipients in the pharmaceutical industry.

167 mulations that are required to have the same excipients in the same amount (qualitative/quantitative

168 e first report that investigates the role of excipients in the supramolecular chemistry of AmB and th

169 ing the presence of appropriate solvents and excipients in their liquid milieu to keep their stabilit

170 tations and high levels of interference from excipients in typical biologic formulations have prevent

171 erived substances are used as pharmaceutical excipients in which medications and reviews published da

172 medicinal products containing phthalates as excipients (inactive ingredients).

173 investigate the impact of a diverse range of excipients including oligosaccharides, polymers, amino a

174 ious factors such as mutations, buffers, and excipients influencing protein aggregation propensity un

175 MD) simulation further validated the protein-excipient interaction sites identified through ssHDX-MS.

176 troscopy (ATR-FTIR) were used to assess drug-excipient interaction.

177 tide levels to assess differences in protein-excipient interactions between two formulations.

178 In addition, drug-excipient interactions can occur.

179 nificant potential for understanding protein-excipient interactions in the solid state and can guide

180 t stability as well as the drug-drug or drug-excipient interactions that affect the aerosol performan

181 API-excipient interactions were observed in high-sensitivity

182 calculated plasma clearance values when the excipient interferes with the quantitation of the dosed

183 of PEG 2000 was incorporated as a functional excipient into silodosin-loaded printlets (3D printed ta

184 We compressed cabotegravir and excipients into cylindrical pellets and heat-sealed them

185 n of topically applied drugs and formulation excipients into porcine skin.

186 and biologics drugs in the presence of sugar excipients into the skin with a duration of 12h.

187 the interaction between the VHH protein and excipients involves hydrophilic interactions and/or hydr

188 The molecular mobility of amorphous excipients is important for the stability of biomaterial

189 iate co-formulation of vaccine antigens with excipients known to influence mucosal barrier functions

190 own copositivity groups, contaminants and/or excipients leading to copositivity, and novel associatio

191 ed combination of findings in a patient with excipient lung disease and preexisting chronic thromboem

192 Excipient lung disease is an uncommon condition that occ

193 ticulate formulations of TMC with a suitable excipient (mannitol) as inhalable particles with tailore

194 deserve their status as inert, many approved excipients may directly modulate physiologically relevan

195 etic model, a ring containing two 1/4-length excipient-modified silicone elastomer cores - each conta

196 The common excipient, N,N-dimethylacetamide (DMA), prevents imminen

197 Nonionic surfactant excipients (NISEs) are commonly added to biologics formu

198 ounts of beta-LG contaminated in the lactose excipient of Inavir could cause immediate allergic react

199 The excipient of potential concern in the AstraZeneca COVID-

200 meric protein from matrix components such as excipients of a biopharmaceutical product and higher mol

201 f both active pharmaceutical ingredients and excipients of a drug tablet.

202 To investigate the effects of vaccine excipients on basophil function, we employed a validated

203 this work were to investigate the impact of excipients on formulation attributes and in vitro perfor

204 rkflow to study the effect of several common excipients on insulin folding stability.

205 In addition, the impact of the excipients on the thermodynamic activity of KTP at conce

206 earing 4T07 or 4T1 grafts (n = 5-6) received excipient or 9.25 or 18.5 MBq of (177)Lu-NM600 as a sing

207 A common solution is to add excipients or hydrotropes that increase solubility and l

208 p53 and Flt3L than in mice receiving Flt3L, excipient, or p53 treatment alone.

209 n to their target tissue, by replacing toxic excipients, or by changing the dosing reqimen.

210 Because of the differences in excipients, paclitaxel dose, and coating morphologies, v

211 to enhanced tabletability without the use of excipients, particle coating, salt, or cocrystal formati

212 e parameters (e.g., type and quantity of the excipient, PCL properties, and implant wall thickness) t

213 These excipient plasma concentrations can result in a 2-5-fold

214 Among tested excipients, polyacrylic acid was best at stabilizing oxy

215 investigation, initial reports suggested the excipient polyethylene glycol 2000-contained in both vac

216 9 vaccines, skin testing (ST) to the vaccine/excipients (polyethylene glycol[PEG] and polysorbate 80

217 ure, pH, salts, detergents, denaturants, and excipients), post-translational modifications, self-asso

218 The excipients present in an amorphous solid dispersion (ASD

219 pable of inactivating the identified azo dye excipients, producing metabolites that no longer inhibit

220 The drug:excipient ratio is restricted to 10:1 w/w to maximise do

221 ained release profiles based upon the active/excipient ratio used.

222 The mechanism of excipient-related signal interference is discussed in re

223 perspective but formulation with additional excipients requires careful evaluation for drug delivery

224 responses (present as low as 0.14% w/w) over excipient responses such as poly(ethylene glycol).

225 utility, we applied the correction to HX-MS excipient screening data collected for a pharmaceuticall

226 ffers an evidence-based approach to rational excipient selection and tailoring of drug release to ach

227 These findings support rational excipient selection in formulation development.

228 Both technical (unit operations, excipient selection, scaling principles) and non-technic

229 We show that it is possible to reduce excipient signals and allow focus on structural characte

230 Both mAb and excipient signals were strongly affected by illumination

231 mic approaches using risk stratification and excipient skin testing.

232 filled with pressure-generating effervescent excipients (sodium bicarbonate, citric acid) and drug in

233 To assess vaccine/excipient ST accuracy in predicting all-severity immedia

234 mRNA COVID-19 vaccine or excipient ST has limited risk assessment utility.

235 e platform, or revaccination without vaccine/excipient ST were excluded.

236 armaceutical scientists to evaluate drug and excipient stability as well as the drug-drug or drug-exc

237 eographical origin maize, a common source of excipient starch, were used to produce a comparison data

238 lity, compatibility with regulatory approved excipients, storage stability (packaging, temperature, h

239 roduced signals >10(4)-fold greater than the excipients studied.

240 The addition of excipients such as mannitol is optimized for both the st

241 The effect of dosing vehicle excipients such as PEG400, propylene glycol, Tween 80, a

242 Common organic excipients such as sucrose, lactose, stearate, dextrin,

243 ive ion mode MS or changing a dosing vehicle excipient, such as substituting propylene glycol for PEG

244 ied depending on the mAb and the presence of excipients, such as polysorbate 80 (PS80) and methionine

245 llows quantitative comparison of formulation excipients, such as sodium chloride, polysorbate, histid

246 urce CID of ions derived from pharmaceutical excipients, sufficiently close in m/z (17.7 ppm mass dif

247 lly examine the effect of key bulking agents/excipients - sugars/polyols - on the material form, stru

248 ne glycol)-poly(glutamic acid) copolymers as excipients suitable to be formulated into a dry powder p

249 e and dextran (and various low concentration excipients targeting different mechanisms of damage), an

250 temperature polyacrylamide-derived copolymer excipient that affords key benefits over traditional exc

251 y incorporating a generally regarded as safe excipient that alters the acoustic properties of the lip

252 ing its propensity to associate with various excipients that can optimize its transfer and retention.

253 products like progesterone gel often contain excipients that cause local toxicity, irritation, and le

254 Ideally, excipients that do not substantially impact drug thermod

255 ing insulin analogues, creating a demand for excipients that limit aggregation.

256 on non-covalent complexation with polymeric excipients, the study provides evidence of intracellular

257 f the dry powder surfactants with lactose as excipient to 40 C and 75% humidity negatively affected h

258 elucidated the interaction between drug and excipient to achieve the AmB aggregation states, and ult

259 f highly water-soluble mannitol or a similar excipient to elicit the high-efficient delivery.

260 protein aggregation and the rational use of excipients to inhibit the process.

261 elivery often use novel lipids as functional excipients to modulate the biodistribution, pharmacokine

262 ulation was performed with several auxiliary excipients to obtain nano-sized amorphous powder formula

263 olymer or a lipid component along with other excipients to stabilize the colloidal system.

264 h involving the addition of certain types of excipients to the aqueous enzyme solution before lyophil

265 thesis and screening of polyacrylamide-based excipients to yield a formulation with pharmacokinetics

266 ndomized to receive rhDNase 2.5 mg in 2.5 ml excipient twice a day (n = 43) or 2.5 ml excipient alone

267 Two polymeric excipients, typically used in enabling drug delivery app

268 Thus, ostensibly unreactive excipients under certain conditions may increase heterog

269 is focused on two clinically significant DCB excipients, urea and shellac, and uses uniaxial mechanic

270 ) is a Food and Drug Administration-approved excipient used to improve the stability and bioavailabil

271 Novel excipients used in pharmaceutical products are subject t

272 We tested 217 variations of excipients using the protein thermal shift assay to gene

273 solution without any molecular precursor or excipient via collaborative interactions (electrostatic,

274 o physical changes to LNP in the presence of excipients via extrapolation of the diffusion coefficien

275 ibe protein complexes with a new 'complexing excipient' - vitamin B(12)-targeted poly(ethylene glycol

276 ride sucrose, which is used as a stabilizing excipient, was quantified to achieve a limit of detectio

277 lites, and sulfobutylether-beta-cyclodextrin excipient were evaluated in hospitalized patients with C

278 Exposures of seven excipients were investigated, and in certain populations

279 the HA mRNA-LNP, but a sufficient amount of excipients were needed to minimize changes in the physic

280 Different ratios between excipients were tested, with the aim to obtain a liquid

281 y important when dealing with pharmaceutical excipients, which are susceptible to economically motiva

282 The present sprays contain organic excipients, which can be irritating, and the BZDs show e

283 ons coated with antiproliferative agents and excipients, whose aim is to foster favorable vessel heal

284 ypromellose, is a traditional pharmaceutical excipient widely exploited in oral sustained drug releas

285 tifies the importance of balancing different excipients with an overall goal of sufficiently reducing

286 verse and abundant small-molecule additives (excipients) with unclear impacts on human physiology, dr

287 improved through the addition of saccharide excipients without detriment to the biological functiona

288 We computed the likelihood that approved excipients would bind to molecular targets.

289 abilized formulation and stability-enhancing excipient yields a significant improvement in lung mRNA